Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?

How do we determine whether Ligand Pharmaceuticals Inc. (NASDAQ:LGND) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that their consensus long positions have historically outperformed the market when we adjust for known risk factors.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) investors should pay attention to a decrease in hedge fund sentiment in recent months. Our calculations also showed that lgnd isn’t among the 30 most popular stocks among hedge funds.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ large-cap stock picks indeed failed to beat the market between 1999 and 2016. However, we were able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that’ll significantly underperform the market. We have been tracking and sharing the list of these stocks since February 2017 and they lost 30.9% through May 30, 2019. That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to.

Ken Griffin CITADEL INVESTMENT GROUP

Let’s take a glance at the latest hedge fund action encompassing Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

How have hedgies been trading Ligand Pharmaceuticals Inc. (NASDAQ:LGND)?

At Q1’s end, a total of 23 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -4% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in LGND over the last 15 quarters. With hedgies’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were upping their holdings considerably (or already accumulated large positions).

No of Hedge Funds with LGND Positions

Among these funds, Renaissance Technologies held the most valuable stake in Ligand Pharmaceuticals Inc. (NASDAQ:LGND), which was worth $178 million at the end of the first quarter. On the second spot was Cardinal Capital which amassed $110.9 million worth of shares. Moreover, Dorset Management, Two Sigma Advisors, and Citadel Investment Group were also bullish on Ligand Pharmaceuticals Inc. (NASDAQ:LGND), allocating a large percentage of their portfolios to this stock.

Due to the fact that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has faced falling interest from the smart money, it’s safe to say that there is a sect of hedge funds that decided to sell off their positions entirely heading into Q3. At the top of the heap, John Osterweis’s Osterweis Capital Management dropped the biggest investment of all the hedgies watched by Insider Monkey, valued at an estimated $7.6 million in stock, and Lawrence Hawkins’s Prosight Capital was right behind this move, as the fund said goodbye to about $1.7 million worth. These transactions are interesting, as total hedge fund interest was cut by 1 funds heading into Q3.

Let’s go over hedge fund activity in other stocks similar to Ligand Pharmaceuticals Inc. (NASDAQ:LGND). We will take a look at Belmond Ltd (NYSE:BEL), PotlatchDeltic Corporation (NASDAQ:PCH), Globant SA (NYSE:GLOB), and BlackLine, Inc. (NASDAQ:BL). All of these stocks’ market caps match LGND’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
BEL 16 347519 -4
PCH 17 336121 2
GLOB 20 65839 5
BL 20 107437 7
Average 18.25 214229 2.5

View table here if you experience formatting issues.

As you can see these stocks had an average of 18.25 hedge funds with bullish positions and the average amount invested in these stocks was $214 million. That figure was $445 million in LGND’s case. Globant SA (NYSE:GLOB) is the most popular stock in this table. On the other hand Belmond Ltd (NYSE:BEL) is the least popular one with only 16 bullish hedge fund positions. Compared to these stocks Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 1.9% in Q2 through May 30th and outperformed the S&P 500 ETF (SPY) by more than 3 percentage points. Unfortunately LGND wasn’t nearly as popular as these 20 stocks and hedge funds that were betting on LGND were disappointed as the stock returned -12.6% during the same period and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as 13 of these stocks already outperformed the market in Q2.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...